Table 2

Prognostic factors for overall survival and progression-free survival

Patient characteristicsCause-specific survivalProgression-free survival
Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
Patient age        
 65–74 years10.0410.441<0.00110.03
 ≥75 years1.43 (1.02 to 1.99) 0.84 (0.53 to 1.32) 1.56 (1.22 to 1.99) 1.88 (1.06 to 3.32) 
Tumor size        
 ≤4 cm1<0.0011<0.0011<0.0011 
 >4 cm2.82 (2.00 to 3.99) 2.10 (1.39 to 3.16) 2.24 (1.74 to 2.87) 1.83 (1.37 to 2.45)<0.001
Histology        
 Endometrioid1<0.00110.021<0.00110.009
 Non-endometrioid2.46 (1.83 to 3.33) 1.68 (1.08 to 2.60) 1.82 (1.43 to 2.33) 1.57 (1.12 to 2.19) 
Grade        
 11 1 1 1 
 20.87 (0.54 to 1.41)0.6  1.17 (0.83 to 1.66)0.37  
 32.17 (1.44 to 3.27)<0.0011.41 (0.79 to 2.54)0.252.11 (1.54 to 2.90)<0.0011.54 (0.97 to 2.45)0.07
LVSI        
 Positive1<0.00110.871<0.00110.5
 Negative0.47 (0.34 to 0.67) 1.07 (0.68 to 1.57) 0.56 (0.44 to 0.71) 0.90 (0.67 to 1.22) 
Myometrial invasion        
 <1/210.00610.1310.00310.24
 ≥1/21.65 (1.16 to 2.35) 0.21 (0.03 to 1.56) 1.48 (1.15 to 1.91) 0.50 (0.16 to 1.58) 
Glandular invasion        
 Positive1<0.00110.281<0.00110.07
 Negative0.50 (0.35 to 0.72) 1.30 (0.81 to 2.08) 0.59 (0.44 to 0.78) 1.43 (0.97 to 2.11) 
Stromal invasion        
 Positive1<0.00110.0091<0.00110.004
 Negative0.27 (0.20 to 0.36) 0.52 (0.32 to 0.85) 0.40 (0.32 to 0.50) 0.53 (0.35 to 0.82) 
Stage        
 I1 1 1 1 
 II3.40 (2.11 to 5.49)<0.0011.49 (0.68 to 1.57)0.322.02 (1.45 to 2.79)<0.0011.08 (0.62 to 1.88)0.8
 III7.64 (5.10 to 10.99)<0.0016.56 (3.70 to 11.40)<0.0013.42 (2.69 to 4.36)<0.0012.83 (1.97 to 4.08)<0.001

  • LVSI, lymphovascular space invasion.